145 related articles for article (PubMed ID: 32873573)
1. Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial.
Multhoff G; Seier S; Stangl S; Sievert W; Shevtsov M; Werner C; Pockley AG; Blankenstein C; Hildebrandt M; Offner R; Ahrens N; Kokowski K; Hautmann M; Rödel C; Fietkau R; Lubgan D; Huber R; Hautmann H; Duell T; Molls M; Specht H; Haller B; Devecka M; Sauter A; Combs SE
Clin Cancer Res; 2020 Oct; 26(20):5368-5379. PubMed ID: 32873573
[TBL] [Abstract][Full Text] [Related]
2. Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study.
Kokowski K; Stangl S; Seier S; Hildebrandt M; Vaupel P; Multhoff G
Strahlenther Onkol; 2019 Apr; 195(4):352-361. PubMed ID: 30747241
[TBL] [Abstract][Full Text] [Related]
3. Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) - From Preclinical Studies to a Clinical Phase II Trial.
Specht HM; Ahrens N; Blankenstein C; Duell T; Fietkau R; Gaipl US; Günther C; Gunther S; Habl G; Hautmann H; Hautmann M; Huber RM; Molls M; Offner R; Rödel C; Rödel F; Schütz M; Combs SE; Multhoff G
Front Immunol; 2015; 6():162. PubMed ID: 25926832
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Hsp70 Serum Levels with Gross Tumor Volume and Composition of Lymphocyte Subpopulations in Patients with Squamous Cell and Adeno Non-Small Cell Lung Cancer.
Gunther S; Ostheimer C; Stangl S; Specht HM; Mozes P; Jesinghaus M; Vordermark D; Combs SE; Peltz F; Jung MP; Multhoff G
Front Immunol; 2015; 6():556. PubMed ID: 26579130
[TBL] [Abstract][Full Text] [Related]
5. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
Yang YJ; Park JC; Kim HK; Kang JH; Park SY
Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
[TBL] [Abstract][Full Text] [Related]
6.
Shevtsov M; Pitkin E; Ischenko A; Stangl S; Khachatryan W; Galibin O; Edmond S; Lobinger D; Multhoff G
Front Immunol; 2019; 10():454. PubMed ID: 30967859
[TBL] [Abstract][Full Text] [Related]
7. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial.
Krause SW; Gastpar R; Andreesen R; Gross C; Ullrich H; Thonigs G; Pfister K; Multhoff G
Clin Cancer Res; 2004 Jun; 10(11):3699-707. PubMed ID: 15173076
[TBL] [Abstract][Full Text] [Related]
8. CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells.
Bashiri Dezfouli A; Yazdi M; Benmebarek MR; Schwab M; Michaelides S; Miccichè A; Geerts D; Stangl S; Klapproth S; Wagner E; Kobold S; Multhoff G
Front Immunol; 2022; 13():883694. PubMed ID: 35720311
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R
Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy--a case report.
Milani V; Stangl S; Issels R; Gehrmann M; Wagner B; Hube K; Mayr D; Hiddemann W; Molls M; Multhoff G
J Transl Med; 2009 Jun; 7():50. PubMed ID: 19549307
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer.
Park TS; Kim HR; Koh JS; Jang SH; Hwang YI; Yoon HI; Chung JH; Kim CH; Kim SS; Kim WS; Jo J; Lee JC; Choi CM
Lung Cancer; 2014 Nov; 86(2):262-7. PubMed ID: 25261232
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.
Guberina M; Eberhardt W; Stuschke M; Gauler T; Aigner C; Schuler M; Stamatis G; Theegarten D; Jentzen W; Herrmann K; Pöttgen C
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1439-1447. PubMed ID: 30710323
[TBL] [Abstract][Full Text] [Related]
13. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study.
Li R; Wang C; Liu L; Du C; Cao S; Yu J; Wang SE; Hao X; Ren X; Li H
Cancer Immunol Immunother; 2012 Nov; 61(11):2125-33. PubMed ID: 22581306
[TBL] [Abstract][Full Text] [Related]
14. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
Nyman J; Friesland S; Hallqvist A; Seke M; Bergström S; Thaning L; Lödén B; Sederholm C; Wagenius G
Lung Cancer; 2009 Jul; 65(1):62-7. PubMed ID: 19081652
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
Deng X; Zheng Z; Lin B; Su H; Chen H; Fei S; Fei Z; Zhao L; Jin X; Xie CY
BMC Cancer; 2017 Jan; 17(1):42. PubMed ID: 28068937
[TBL] [Abstract][Full Text] [Related]
16. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
[TBL] [Abstract][Full Text] [Related]
17. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
[TBL] [Abstract][Full Text] [Related]
18. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
[TBL] [Abstract][Full Text] [Related]
19. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
20. Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience.
Yilmaz U; Yılmaz U; Yasar Z; Kıraklı EK; Ulger S; Ozdogan Y; Demirci NY; Erol S; Ozdogan I; Sahin B; Koksal D; Akcay C
J Cancer Res Ther; 2016; 12(1):334-9. PubMed ID: 27072260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
